Therapeutic drug monitoring of antimicrobials

British Journal of Clinical Pharmacology

Volumn 73, Issue 1, 2012, Pages 27-36

  Roberts, Jason A ^a,b   Norris, Ross ^a,c,d   Paterson, David L ^a,b   Martin, Jennifer H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c MATER HOSPITAL   (Australia)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

Antibacterial; Antibiotic; Assay pharmacokinetics; Pharmacodynamics; Target concentration intervention; Therapeutic drug management

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; ISONIAZID; LINCOSAMIDE; LINEZOLID; METRONIDAZOLE; QUINOLONE DERIVATIVE; RIFAMPICIN; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL GROWTH; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CONTINUOUS INFUSION; COST CONTROL; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; HUMAN; LACTIC ACIDOSIS; LOWER RESPIRATORY TRACT INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; STEADY STATE; TIMED DRUG RELEASE; TOXICITY;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG RESISTANCE, MICROBIAL; HUMANS; PATIENT COMPLIANCE;

EID: 83155176073     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04080.x     Document Type: Review

References (100)

1. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45: 755-73.
2. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31: 2742-51.
3. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
4. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
5. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-68.
6. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53: 24-34.
7. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30: 167-72.
8. Begg EJ, Barclay ML, Kirkpatrick CJ. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 1999; 47: 23-30.
9. Roberts JA, Hope WW, Lipman J. Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? Int J Antimicrob Agents 2010; 35: 419-20.
10. Roberts JA, Lipman J. A pilot evaluation of a beta-lactam therapeutic drug monitoring program in critically ill patients. Australian & New Zealand Intensive Care Society Annual Scientific Meeting; 2009; Perth; 2009.
11. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-12.
12. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug. Nat Rev Microbiol 2004; 2: 289-300.
13. Holford NH. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 2001; 52 (Suppl. 1): 55S-9S.
14. Matthews I, Kirkpatrick C, Holford N. Quantitative justification for target concentration intervention - parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 2004; 58: 8-19.
15. Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotech 2011; PMID 21554211.
16. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840-51.
17. Bilgrami I, Roberts JA, Wallis SC, Thomas J, Davis J, Fowler S, Goldrick PB, Lipman J. Meropenem dosing in critically ill patients with sepsis recieving high volume continuous veno-venous hemofiltration. Antimicrob Agents Chemother 2010; 54: 2974-8.
18. Li AM, Gomersall CD, Choi G, Tian Q, Joynt GM, Lipman J. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother 2009; 64: 929-37.
19. Lipman J, Wallis SC, Boots RJ. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 2003; 97: 1149-54.
20. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.
21. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-31.
22. Kirkpatrick CM, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999; 47: 637-43.
23. Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 1993; 21: 172-3.
24. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008; 30: 674-81.
25. Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977; 21: 362-9.
26. MacGowan A, Reeves D. Serum aminoglycoside concentrations: the case for routine monitoring. J Antimicrob Chemother 1994; 34: 829-37.
27. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605-9.
28. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-5.
29. Begg EJ, Barclay ML. Aminoglycosides - 50 years on. Br J Clin Pharmacol 1995; 39: 597-603.
30. Martin JH, Ah Yui N, Norris R, Kubler P, Barras M, Kirkpatrick CMJ. Optimising gentamicin use in a tertiary hospital setting. Australasian Society for Clinical and Experimental Pharmacology and Toxicology; 2010; Melbourne; 2010.
31. Avent M, Teoh JL, Lees J, Eckert KA, Kirkpatrick CMJ. Comparing three methods of monitoring gentamicin concentrations in febrile neutropaenic patients. Ther Drug Monit 2011; (in press).
32. Finnell DL, Davis GA, Cropp CD, Ensom MH. Validation of the Hartford nomogram in trauma surgery patients. Ann Pharmacother 1998; 32: 417-21.
33. El Bakri F, Pallett A, Smith AG, Duncombe AS. Ototoxicity induced by once-daily gentamicin. Lancet 1998; 351: 1407-8.
34. Antibiotic Expert Group, ed. Therapeutic Guidelines: Antibiotic (Version 14). Melbourne: Therapeutic Guidelines Ltd, 2010.
35. Drusano GL, Louie A. Optimization of Aminoglycoside Therapy. Antimicrob Agents Chemother 2011; 55: 2528-31.
36. Duffull SB, Kirkpatrick CM, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol 1997; 43: 125-35.
37. van Lent-Evers NA, Mathôt RA, Geus WP, van Hout BA, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999; 21: 63-73.
38. Norris R, Martin J, Thompson E, Ray J, Fullinfaw R, Joyce D, Barras M, Jones G, Morris R. Current status of therapeutic drug monitoring in Australai and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional development. Ther Drug Monit 2010; 32: 615-23.
39. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-42.
40. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
41. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-7.
42. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, Kollef MH. Predictors of Mortality for Methicillin-Resistant Staphylococcus aureus Health-Careâ€"Associated Pneumonia*. Chest 2006; 130: 947-55.
43. Potoski BA, Paterson DL. Appropriate Pharmacokinetic Index for Outcome in Staphylococcus aureus Pneumonia. Chest 2007; 132: 1101-3.
44. Patanwala AE, Norris CJ, Nix DE, Kopp BJ, Erstad BL. Vancomycin dosing for pneumonia in critically ill trauma patients. J Trauma 2009; 67: 802-4.
45. Pea F, Viale P. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin Pharmacokinet 2008; 47: 147-52.
46. Roberts JA, Taccone FS, Udy AA, Jacobs F, Louis J-L, Lipman J. Vancomycin dosing in critically ill patients - robust methods for improved continuous infusion regimens. Antimicrob Agents Chemother 2011; 55: 2704-9.
47. Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 2006; 12: 92-5.
48. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
49. Rello J, Sole-Violan J, Sa-Borges M, Garnacho-Montero J, Munoz E, Sirgo G, Olona M, Diaz E. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33: 1983-7.
50. Lipman J. Is the end-game penetration (of the airway)? Crit Care Med 2005; 33: 1654-5.
51. Garrelts JC, Godley PJ, Horton MW, Karboski JA. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. Clin Pharm 1987; 6: 795-9.
52. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25: 433-7.
53. Moellering RC Jr. Pharmacokinetics of vancomycin. J Antimicrob Chemother 1984; 14 (Suppl. D): 43-52.
54. Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, Viale P. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009; 53: 1863-7.
55. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
56. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger Vancomycin Doses (>=4 grams/day) are Associated with an Increased Incidence of Nephrotoxicity. Antimicrob Agents Chemother 2008; 62: 1138-41.
57. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29: 1275-9.
58. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000; 39: 167-83.
59. Harding I, MacGowan AP, White LO, Darley ES, Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 2000; 45: 835-41.
60. Brink AJ, Richards GA, Cummins RR, Lambson J. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int J Antimicrob Agents 2008; 32: 455-8.
61. Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother 2003; 51: 971-5.
62. Kingery JR, Sowinski KM, Kraus MA, Klaunig JE, Mueller BA. Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis. Pharmacotherapy 2000; 20: 653-6.
63. Smith PF, Petros WP, Soucie MP, Copeland KR. New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease. Ther Drug Monit 1998; 20: 231-5.
64. Cavenaghi L, Corti A, Cassani G. Comparison of the solid phase enzyme receptor assay (SPERA) and the microbiological assay for teicoplanin. J Hosp Infect 1986; 7 (Suppl. A): 85-9.
65. Rybak MJ, Bailey EM, Reddy VN. Clinical evaluation of teicoplanin fluorescence polarization immunoassay. Antimicrob Agents Chemother 1991; 35: 1586-90.
66. Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005; 39: 32-8.
67. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51: 1725-30.
68. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44: 357-63.
69. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-51.
70. Bakker-Woudenberg IA, Roosendaal R. Impact of dosage schedule of antibiotics on the treatment of serious infections. Intensive Care Med 1990; 16: S229-34.
71. Craig W. Pharmacokinetic and experimental data on beta-lactam antibiotics in the treatment of patients. Eur J Clin Microbiol Infect Dis 1984; 3: 575-8.
72. Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997; 41: 733-8.
73. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-47.
74. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985; 15 (Suppl. A): 37-46.
75. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994; 38: 931-6.
76. Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care 2007; 13: 598-606.
77. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel BM. Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 1989; 8: 878-87.
78. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986; 108: 835-40.
79. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14: R126.
80. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010; 36: 332-9.
81. Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents 2002; 19: 349-53.
82. Blondiaux N, Wallet F, Favory R, Onimus T, Nseir S, Courcol RJ, Durocher A, Roussel-Delvallez M. Daily serum piperacillin monitoring is advisable in critically ill patients. Int J Antimicrob Agents 2010; 35: 500-3.
83. Connor MJ Jr, Salem C, Bauer SR, Hofmann CL, Groszek J, Butler R, Rehm SJ, Fissell WH. Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis. Antimicrob Agents Chemother 2011; 55: 557-60.
84. Samanidou VF, Evaggelopoulou EN, Papadoyannis IN. Development of a validated HPLC method for the determination of four penicillin antibiotics in pharmaceuticals and human biological fluids. J Sep Sci 2006; 29: 1550-60.
85. McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JP. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr 2010; 878: 2039-43.
86. Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 2010; 32: 97-101.
87. Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010; 54: 4605-10.
88. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-23.
89. Di Paolo A, Malacarne P, Guidotti E, Danesi R, Del Tacca M. Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet 2010; 49: 439-47.
90. Ehrlich M, Trittler R, Daschner FD, Kummerer K. A new and rapid method for monitoring the new oxazolidinone antibiotic linezolid in serum and urine by high performance liquid chromatography-integrated sample preparation. J Chromatogr B Biomed Sci Appl 2001; 755: 373-7.
91. Toutain J, Boselli E, Djabarouti S, Allaouchiche B, Xuereb F, Bernadou JM, Ba B, Saux MC, Breilh D. Determination of linezolid in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. J Chromatogr 2004; 813: 145-50.
92. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81.
93. Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic resistance - what's dosing got to do with it? Crit Care Med 2008; 36: 2433-40.
94. Pea F, Poz D, Viale F, Furlanut M. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM based retrospective perspective J Antimicrob Chemother 2006; 58: 380-6.
95. Gous A, Lipman J, Scribante J, Tshukutsoane S, Hon H, Pinder M, Mathivha R, Verhoef L, Stass H. Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. Int J Antimicrob Agents 2005; 26: 50-5.
96. Kamberi M, Tsutsumi K, Kotegawa T, Nakamura K, Nakano S. Determination of ciprofloxacin in plasma and urine by HPLC with ultraviolet detection. Clin Chem 1998; 44: 1251-5.
97. Sun HW, He P, Lv YK, Liang SX. Effective separation and simultaneous determination of seven fluoroquinolones by capillary electrophoresis with diode-array detector. J Chromatogr 2007; 852: 145-51.
98. Ray J, Gardiner I, Marriott D. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J 2003; 33: 229-34.
99. Peloquin CA. Serum concentrations of the antimycobacterial drugs. Chest 1998; 113: 1154-5.
100. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-83.